Cardiorenal effects of SGLT2 inhibitors: who might benefit?

References

• The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee. The 2017 SEMDSA Guideline for the Management of Type 2 Diabetes. J Endocrinol Metab Diab SA. 2017;21(1):S1–S196.
   Google Scholar
• Kok A, Hariram A, Webb D, Amod A. Patterns of diabetes management in South Africa: baseline and 24-month data from the South African cohort of the DISCOVER study. J Endocrinol Metab Diab SA. 2021;26(2):60–65. https://doi.org/10.1080/16089677.2021.1897227
   Web of Science ®Google Scholar
• Blonde L, Aschner P, Bailey C, Ji L, Leiter LA, Matthaei S. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diab Vasc Dis Res. 2017;14(3):172–183. https://doi.org/10.1177/1479164116679775
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–e324. https://doi.org/10.1161/CIR.0000000000000691
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease. challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. https://doi.org/10.2215/CJN.11491116
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. https://doi.org/10.1186/s12933-018-0728-6
   PubMed Web of Science ®Google Scholar
• Pálsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):273–280. https://doi.org/10.1053/j.ackd.2014.03.003
   PubMed Web of Science ®Google Scholar
• Khan H, Anker SD, Januzzi JL, et al. Heart failure epidemiology in patients with diabetes mellitus without coronary heart disease. J Card Fail. 2019;25, 2, 78–86. https://doi.org/10.1016/j.cardfail.2018.10.015
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987
   PubMed Web of Science ®Google Scholar
• Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465–2474. https://doi.org/10.1007/s00125-014-3369-7
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2022. Diabetes Care. 2022;45(S1):S125–S143. https://doi.org/10.2337/dc22-S009
   PubMedGoogle Scholar
• Fontes-Carvalho R, Santos-Ferreira D, Raz I, et al. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol. 2021 Feb 28;29(9):1352–1360. https://doi.org/10.1093/eurjpc/zwab034
   Web of Science ®Google Scholar
• Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929–944. https://doi.org/10.1161/CIRCULATIONAHA.117.028814
   PubMed Web of Science ®Google Scholar
• Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e878. https://doi.org/10.1161/CIR.0000000000000664
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22(1):39–52. https://doi.org/10.1007/s11892-021-01442-z
   PubMed Web of Science ®Google Scholar
• Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105(5):1213–1223. https://doi.org/10.1002/cpt.1307
   PubMed Web of Science ®Google Scholar
• Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021;26(3):623–642. https://doi.org/10.1007/s10741-020-10038-w
   PubMed Web of Science ®Google Scholar
• Lopashuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors. JCC Basic Transl Sci. 2020;5(6):632–644. https://doi.org/10.1016/j.jacbts.2020.02.004
   PubMedGoogle Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. https://doi.org/10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Neal B, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors: are they All the same? A narrative review of cardiovascular outcome trials. Diabetes Ther. 2021;12(1):55–70. https://doi.org/10.1007/s13300-020-00951-6
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol. 2021;6(2):148–158. https://doi.org/10.1001/jamacardio.2020.4511
   PubMed Web of Science ®Google Scholar
• Neuen BL, Amott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diab Obes Metab. 2021;23(2):382–390. https://doi.org/10.1111/dom.14226
   PubMed Web of Science ®Google Scholar
• Nakagaito M, Imamura T, Joho S. Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure. BMC Cardiovasc Disord. 2021;21(1):347. https://doi.org/10.1186/s12872-021-02163-7
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease? Nephrol Dial Transplant. 2020;35(S1):i33–i42. https://doi.org/10.1093/ndt/gfz264
   PubMedGoogle Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. https://doi.org/10.1016/S2213-8587(19)30180-9
   PubMed Web of Science ®Google Scholar
• Aguilar-Gallardo JS, Correa A, Contreras JP, et al. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):311–321. https://doi.org/10.1093/ehjcvp/pvab056
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. https://doi.org/10.1016/S0140-6736(20)31824-9
   PubMed Web of Science ®Google Scholar
• Kalra S, Aydin H, Sahay M, et al. Cardiorenal syndrome in type 2 diabetes mellitus – rational Use of sodium-glucose cotransporter-2 inhibitors. Eur Endocrinol. 2020;16(2):113–121. https://doi.org/10.17925/EE.2020.16.2.113
   PubMedGoogle Scholar
• Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovas Diabetol. 2022;21(1):47. https://doi.org/10.1186/s12933-022-01476-x
   PubMed Web of Science ®Google Scholar
• Pattorno E, Htoo PATIENT, Glynn RJ, et al. Sodium-Glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174(11):1528–1541. https://doi.org/10.7326/M21-0893
   PubMed Web of Science ®Google Scholar
• Giugliano D, Longo M, Scappaticcio L, et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20(1):236. https://doi.org/10.1186/s12933-021-01430-3
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• de Boer IH, Caramori L, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Kdigo 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4):S1–S115. https://doi.org/10.1016/j.kint.2020.06.019
   PubMed Web of Science ®Google Scholar
• Packer M, Metra M. Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. Eur J Heart Fail. 2020;22(10):1759–1767. https://doi.org/10.1002/ejhf.1857
   PubMed Web of Science ®Google Scholar
• Caffrey AR, Borelli EP. The art and science of drug titration. Ther Adv Drug Saf. 2020;11:204209862095891-14. https://doi.org/10.1177/2042098620958910
   Web of Science ®Google Scholar
• Iglay K, Sawhney B, Fu AZ. Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes. Endocrinol Diab Metab. 2020;3(1):e00107. https://doi.org/10.1002/edm2.107
   PubMedGoogle Scholar
• Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G. Drug titration patterns and HbA1c levels in type 2 diabetes. Int J Clin Pract. 2009;63(7):1008–1016. https://doi.org/10.1111/j.1742-1241.2009.02094.x
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction. The CHAMP-HF registry. Am Coll Cardiol. 2018;72(4):351–366. https://doi.org/10.1016/j.jacc.2018.04.070
   PubMed Web of Science ®Google Scholar
• Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(19):2365–2383. https://doi.org/10.1016/j.jacc.2019.02.015
   PubMed Web of Science ®Google Scholar
• Teng T-HK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6(9):e1008–e1018. https://doi.org/10.1016/S2214-109X(18)30306-1
   PubMed Web of Science ®Google Scholar
• Patel R, Fonarow GC, Greene SJ, et al. Kidney function and outcomes in patients Hospitalised with heart failure. J Am Coll Cardiol. 2021;78(4):330–343. https://doi.org/10.1016/j.jacc.2021.05.002
   PubMed Web of Science ®Google Scholar
• Gracia E, Hamid A, Butler J. Timely management of new-onset heart failure. Circulation. 2019;140(8):621–623. https://doi.org/10.1161/CIRCULATIONAHA.118.035452
   PubMed Web of Science ®Google Scholar
• Paul SK, Klein K, Thorstead BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):100. https://doi.org/10.1186/s12933-015-0260-x
   PubMedGoogle Scholar
• Reach G, Pechtner C, Gentilella R, et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diab Metab. 2017;43(6):501–511. https://doi.org/10.1016/j.diabet.2017.06.003
   PubMed Web of Science ®Google Scholar
• Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. Br Med J. 2021;373(1091):n1091. https://doi.org/10.1136/bmj.n1091
   PubMedGoogle Scholar
• Verma S, Klug E, Mareev VY, et al. Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Curr Opin Cardiol. 2020;35(5):589–601. https://doi.org/10.1097/HCO.0000000000000774
   PubMed Web of Science ®Google Scholar
• Marx N. Cardiovascular risk assessment in diabetes and pre-diabetes. In Camm AJ, Lüscher TF, Maurer G, Serruys PW, editors. Esc VardioMed, 3rd ed. Oxford University Press, 2018. https://doi.org/10.1093/med/9780198784906.003.0216
   Google Scholar
• American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of medical care in diabetes – 2022. Diabetes Care. 2022;45(S1):S175–S184. https://doi.org/10.2337/dc22-S011
   PubMedGoogle Scholar
• Qiu M, Zhao L-M, Zhan Z-L. Comprehensive analysis of adverse events associated with SGLT2is: a meta-analysis involving nine large randomized trials. Front Endocrinol. 2021. Dec;2:743807. https://doi.org/10.3389/fendo.2021.743807
   Google Scholar
• Lam D, Shaikh A. Real-Life prescribing of SGLT2 inhibitors: How to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360. 2021;2(4):742–746. https://doi.org/10.34067/KID.0000412021
   PubMedGoogle Scholar
• Dave CV, Schneeweiss S, Kim D, et al. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. Ann Intern Med. 2019;171(4):248–256. https://doi.org/10.7326/M18-3136
   PubMed Web of Science ®Google Scholar
• Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients With CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463–1476. https://doi.org/10.1016/j.ekir.2022.04.094
   PubMed Web of Science ®Google Scholar
• Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. https://doi.org/10.1186/s12933-020-01197-z
   PubMed Web of Science ®Google Scholar
• EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with Chronic Kidney Disease. N Engl J Med. 2023;388, 2, 117–127. Online ahead of print. https://doi.org/10.1056/NEJMoa2204233
   PubMed Web of Science ®Google Scholar
• Li N, Zhu X, Wei P, et al. Effects of SGLT2 inhibitors on renal outcomes in patients with Chronic Kidney Disease: a meta-analysis. Front Med. 8:728089. https://doi.org/10.3389/fmed.2021.728089
   Google Scholar
• The Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the proper use of SGLT2 inhibitors. J Diabetes Investig. 2020;11(1):257–261. https://doi.org/10.1111/jdi.13160
   PubMed Web of Science ®Google Scholar
• Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147–1154. https://doi.org/10.2337/dc18-2316
   PubMed Web of Science ®Google Scholar
• Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. Clinical and Biochemical Differences. Arch Intern Med. 2004;164(17):1925–1931. https://doi.org/10.1001/archinte.164.17.1925
   PubMedGoogle Scholar
• Vlachopoulos C, Terentes-Printzios D, Tsioufis K. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly. Eur Heart J. 2021;42(18):1739–1741. https://doi.org/10.1093/eurheartj/ehaa1022
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Raz I, Mosenzon O, et al. Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes. JAMA Cardiol. 2021;6(7):801–810. https://doi.org/10.1001/jamacardio.2021.0660
   PubMed Web of Science ®Google Scholar
• Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43(5):416–424. https://doi.org/10.1093/eurheartj/ehab798
   PubMed Web of Science ®Google Scholar
• Herrington WG, Frankel AH, Wonnacott A, Webb D, Watt A, Watson M, et al. for the UK Kidney Association (UKKA). UK Kidney Association clinical practice guideline: sodium-glucose Co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. October 2021. https://ukkidney.org/renal-association/news/sglt-2-inhibition-adults-kidney-disease
   Google Scholar
• Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022;37(7):1317–1329. https://doi.org/10.1093/ndt/gfac040
   PubMed Web of Science ®Google Scholar